CCL2/TIMP1 Axis Identified as Key Driver in Glioblastoma's Immunosuppressive Microenvironment
A high-risk signature centered on CCL2 and TIMP1 was identified, linked to an inflammatory, macrophage-enriched microenvironment in glioblastoma.
Asset / Drug
Drug and asset intelligence for CCL2 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.